Skip to main content

Bioventus, Inc. (BVS)

NASDAQ: BVS · IEX Real-Time Price · USD
15.28 0.87 (6.04%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap850.18M
Revenue (ttm)376.09M
Net Income (ttm)n/a
Shares Out41.81M
EPS (ttm)-0.26
PE Ration/a
Forward PE10.04
Dividendn/a
Ex-Dividend Daten/a
Volume314,364
Open14.41
Previous Close14.41
Day's Range14.28 - 15.33
52-Week Range10.74 - 19.94
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 9, 2021

About BVS

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, c...

IndustryDiagnostics & Research
IPO DateFeb 11, 2021
Employees900
Stock ExchangeNASDAQ
Ticker SymbolBVS
Full Company Profile

Financial Performance

In 2020, Bioventus's revenue was $321.16 million, a decrease of -5.58% compared to the previous year's $340.14 million. Earnings were $16.41 million, an increase of 139.54%.

Financial Statements

News

BIOVENTUS INC. and MISONIX, INC.

DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) and Misonix, Inc. (Nasdaq: MSON) (“Misonix”), today announced an election deadline of 5:00 p.m., New Yo...

5 days ago - GlobeNewsWire

3 Small Biotech Stocks in Focus on World Arthritis Day

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

Other symbols:ABBVALPNAMGNIMABJNJ
1 week ago - Zacks Investment Research

DUROLANE® Among High-Molecular Weight Hyaluronic Acid Treatments Linked to Significant Improvements in Knee Osteoarth...

DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc., (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in innovations for active healing, announced that the American Academy of Orthopae...

1 month ago - GlobeNewsWire

Bioventus Proceeds with Option Structure Agreement with CartiHeal

DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has elected to make a $50 million escrow p...

1 month ago - GlobeNewsWire

Bioventus Invests in Trice Medical Minimally Invasive Technologies

Bioventus Also Agrees to OUS Distribution and Co-Development Relationships Bioventus Also Agrees to OUS Distribution and Co-Development Relationships

1 month ago - GlobeNewsWire

Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer

DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Dave Crawford as its Vice Pr...

2 months ago - GlobeNewsWire

SV Health Investors Announces Three Realizations in its Growth Equity Portfolio

BOSTON, Aug. 19, 2021 /PRNewswire/ -- SV Health Investors ("SV"), a leading global health care investment firm, is pleased to announce a series of realizations from its growth equity portfolio: On Augus...

Other symbols:HRC
2 months ago - PRNewsWire

Will a Powerful Acquisition Make This Early 2021 IPO a Buy?

Maybe the equivalent of an extra full quarter of revenue will get the attention of investors.

Other symbols:MSONSNN
2 months ago - The Motley Fool

SHAREHOLDER ALERT: WeissLaw LLP Investigates Misonix, Inc.

NEW YORK, July 30, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Misonix, Inc. ("Misonix" or the "Compan...

Other symbols:MSON
2 months ago - PRNewsWire

Bioventus Scoops Up Misonix In $518M Stock & Cash Deal; Raises FY21 Sales Outlook

Recently listed Bioventus Inc (NASDAQ: BVS) has agreed to acquire Misonix Inc (NASDAQ: MSON) for $518 million in a cash-and-stock transaction. Misonix stockholders may elect to receive either 1.6839 Bio...

Other symbols:MSON
2 months ago - Benzinga

Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix

The Combination Further Differentiates Bioventus' Product Portfolio and Accelerates Its Revenue Growth The Combination Further Differentiates Bioventus' Product Portfolio and Accelerates Its Revenue Growth

2 months ago - GlobeNewsWire

Bioventus Inc. Reports Preliminary Second Quarter Net Sales; Updates Full-Year 2021 Net Sales Guidance

DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported preliminary financial resul...

2 months ago - GlobeNewsWire

Bioventus® Management to Present at Canaccord Genuity Growth Conference and Morgan Stanley Virtual Global Healthcare ...

DURHAM, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Senior management of Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present at the C...

2 months ago - GlobeNewsWire

Bioventus Appoints Mary Kay Ladone to Board of Directors

DURHAM, N.C., July 14, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has announced the appointment of Mary Kay ...

3 months ago - GlobeNewsWire

Bioventus Launches OSTEOAMP® SELECT Flowable Nationwide

DURHAM, N.C., July 13, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, is launching OSTEOAMP SELECT Flowable, a f...

3 months ago - GlobeNewsWire

Bioventus Invests in Vaporox

Ultrasonic Technology to Heal Diabetic Foot Ulcers Ultrasonic Technology to Heal Diabetic Foot Ulcers

3 months ago - GlobeNewsWire

Bioventus to Release Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021

DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that second quarter of fis...

4 months ago - GlobeNewsWire

Will Bioventus (BVS) Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor of Bioventus (BVS).

4 months ago - Zacks Investment Research

Bioventus Senior Management to Present at Upcoming Investor Conferences

DURHAM, N.C., May 17, 2021 (GLOBE NEWSWIRE) -- Senior management of Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present at the Ca...

5 months ago - GlobeNewsWire

Bioventus Inc. Reports First Quarter Results; Updates Full Year 2021 Financial Guidance

DURHAM, N.C., May 12, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three ...

5 months ago - GlobeNewsWire

Bioventus Announces First Commercial Shipment of the Bioness® Integrated Therapy System (BITS) Balance System

Fourteen Facilities Across the US Receive Multidisciplinary Therapy Solution Fourteen Facilities Across the US Receive Multidisciplinary Therapy Solution

5 months ago - GlobeNewsWire

Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021

DURHAM, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that first quarter of fis...

6 months ago - GlobeNewsWire

Bioventus Acquires Bioness, Inc.

DURHAM, N.C., March 30, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has acquired Bioness, Inc. (“Bioness”), a...

6 months ago - GlobeNewsWire

Bioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Guidance

DURHAM, N.C., March 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the ...

6 months ago - GlobeNewsWire

Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS™ (PTP-001) for the Treatment of Knee OA

DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in solutions for innovative healing, reported that the first patients have been enr...

7 months ago - GlobeNewsWire